Please provide your email address to receive an email when new articles are posted on . As presbyopia-correcting drops have started to enter the marketplace, many anterior segment surgeons are talking ...
The FDA accepted a supplemental new drug application to expand the indication for Ryzumvi to include the treatment of ...
Opus Genetics and Viatris, Inc. (Viatris) (through its affiliate) are parties to a global licensing agreement which provides for the development of phentolamine ophthalmic solution 0.75% and grants ...
TECLens treated the first patient in a first-in-human trial assessing safety and efficacy of qCXL-based refractive correction ...
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for ...
Patients who have a new type of lens implanted in their eyes during surgery for cataracts or to correct their eyesight have excellent or good vision over distances both near and far, and often no ...
Researchers estimate that about 1.8 billion people around the world live with presbyopia, a farsightedness condition that can appear as a person grows older. More recent treatment options for ...
Advanced technology lenses work best in pristine eyes. Problems with ocular alignment, pupil size, ocular surface disease, irregular astigmatism, corneal dystrophies, scarring, and diseases of the ...
Did you know that with the passage of time our sight fails more and more? However, there is a new prescription eye drop approved by the U.S. that promises to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results